A Multicenter Study of Secukinumab, With a Randomized Double-blind, Placebo-controlled Withdrawal-retreatment Period, to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission
Latest Information Update: 23 Aug 2026
At a glance
- Drugs Secukinumab (Primary)
- Indications Non-radiographic axial spondyloarthritis
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharma A.G.
Most Recent Events
- 02 Jun 2026 Planned End Date changed from 13 Jun 2028 to 4 Apr 2028.
- 02 Jun 2026 Planned primary completion date changed from 19 Apr 2028 to 8 Feb 2028.
- 18 Dec 2025 Planned End Date changed from 21 Jun 2030 to 13 Jun 2028.